Although the mortality of patients with high-risk pulmonary embolism has decreased over time, the decrease cannot be attributed to improved treatments for pulmonary embolism.
Study authors assessed the risk of stroke and systemic embolism in patients with atrial fibrillation and heart failure according to HF types.
The AstraZeneca vaccine, developed with researchers from Oxford University, has been heavily used in Britain
Cardiovascular outcomes were found to be worse among Black vs White pregnant and postpartum women.
Anticoagulants, antiplatelets, and thrombolytics for the treatment and/or prophylaxis of venous and arterial thrombosis.
The surgical management of patients with massive pulmonary embolism and high-risk submassive PE was found to be safe and highly effective for achieving right ventricular recovery.
Limited tablet cardiac ultrasound was found to represent an effective alternative to standard platform imaging for the screening of COVID-19-related cardiac conditions.
Treatment with statins was found to reduce the risk for disease recurrence in patients with venous thromboembolism.
In patients with abnormal vital signs presenting to the emergency department who are suspected of having a pulmonary embolism, a negative focused cardiac ultrasound examination may be associated with reduced odds of a pulmonary embolism diagnosis.
Current guidelines recommend 5 weeks of postoperative prophylactic anticoagulation, but a new study suggests the duration of this treatment ought to be extended.
